Risperidone is a second generation or atypical antipsychotic. Risperidone is contribute to treat
schizophrenia which includes adolescent schizophrenia, schizoaffective
disorder, the mixed and manic states associated with bipolar disorder, and
irritability in people with autism. Risperidone
is associated with significant weight gain and metabolic problems, as well as
tardive dyskinesia and neuroleptic malignant syndrome. Risperidone was developed by Janssen-Cilag and first released in
1994.
No comments:
Post a Comment